FMGE obstetrics & gynaecology questions

The fundal height correlates approximately with gestational age during the second and early third trimester when measured by abdominal palpation. At 20 weeks, the uterine fundus reaches the level of the umbilicus. At 28 weeks, the fundus is roughly midway between the umbilicus and the xiphisternum, and by 36 weeks it approaches the xiphisternum. This clinical correlation is used as a quick bedside estimate of gestational age in resource-limited antenatal settings.

• A. At 36 weeks the fundus is near or at the level of the xiphisternum.
• B. At 32 weeks the fundus is higher, closer to the xiphisternum.
• C. At 28 weeks the fundus is typically midway between the umbilicus and xiphisternum, not at the umbilicus.

A pregnant woman with no prior history of tetanus immunization should receive two doses of tetanus toxoid (TT1 and TT2) given at least four weeks apart, with the second dose completed at least two to four weeks before the expected date of delivery. This primary series protects both the mother from puerperal tetanus and the newborn from neonatal tetanus through passive antibody transfer. If she had received TT in a previous pregnancy within the last three years, only a single booster dose would be required.

• A. Tetanus toxoid must be completed before delivery to protect against neonatal tetanus, not deferred to after.
• C. Three doses are not required in this schedule; two doses suffice for primary immunization in pregnancy.
• D. A single dose does not provide adequate protective antibody levels for a previously unimmunized woman.

The triple marker test, performed between 15 and 20 weeks of gestation, measures maternal serum alpha-fetoprotein, total human chorionic gonadotropin, and unconjugated estriol to screen for trisomy 21, trisomy 18, and neural tube defects. In contrast, the double marker test is done earlier, at 11-13 weeks, and measures free beta-hCG and PAPP-A, often combined with nuchal translucency on ultrasound. The quadruple test adds inhibin-A to the three triple test markers, improving detection rates further.

• A. Nuchal translucency is an ultrasound measurement, not a biochemical serum test.
• B. The double marker test measures free beta-hCG and PAPP-A in the first trimester, not these three analytes.
• D. The quadruple test includes inhibin-A in addition to the three markers described, which is not mentioned here.

The fetal anomaly scan, also called the targeted imaging for fetal anomalies (TIFFA) scan, is best performed at 18-20 weeks of gestation. At this stage, fetal organs including the brain, heart, spine, kidneys, and limbs are sufficiently developed and large enough to be visualized in detail, allowing detection of major structural malformations. This timing also allows adequate time for further evaluation or counseling if an anomaly is detected, within legal limits for termination in India.

• B. This earlier window is used for nuchal translucency and dating scans, not detailed anomaly assessment.
• C. This later timing is used for growth and Doppler assessment, too late for optimal anomaly detection and counseling.
• D. Fetal structures are still too small at this stage for comprehensive anomaly evaluation.

Under India's national program for prevention of anemia in pregnancy, pregnant women are given one tablet daily containing 60 mg of elemental iron and 500 micrograms of folic acid, for a minimum of 100 days starting after the first trimester. This dose addresses the increased iron and folate requirements of pregnancy to support maternal hemoglobin synthesis and fetal neural development. Supplementation continues through the postpartum period for 100 days as well.

• A. Neither the iron nor the folic acid dose matches the standard program formulation.
• B. The folic acid dose is correct but the iron dose given under the program is 60 mg, not 100 mg.
• C. The iron dose is correct but the folic acid content in the program's formulation is 500 mcg, not 400 mcg.

Preeclampsia is defined as new-onset blood pressure ≥140/90 mmHg after 20 weeks of gestation in a previously normotensive woman, accompanied by proteinuria of ≥300 mg per 24 hours (or equivalent protein/creatinine ratio), or in the absence of proteinuria, evidence of end-organ dysfunction. This patient meets both the BP threshold and the 24-hour urinary protein criterion of ≥300 mg. Dipstick testing is unreliable and a negative dipstick does not exclude preeclampsia when quantitative proteinuria is diagnostic. The onset after 20 weeks with no prior hypertension history distinguishes this from chronic hypertension.

• A. Gestational hypertension requires absence of proteinuria or end-organ dysfunction, which is not the case here.
• C. This is not a recognized diagnostic category in current classifications.
• D. Chronic hypertension implies hypertension predating pregnancy or diagnosed before 20 weeks, which is not described.

Magnesium sulfate is the drug of choice for both prevention and treatment of seizures in eclampsia, as established by multiple large randomized trials including the MAGPIE trial showing superiority over phenytoin and diazepam. It acts by antagonizing calcium at the neuromuscular junction and NMDA receptors, causing cerebral vasodilation and reducing neuronal excitability. The standard regimen is the Pritchard regimen (loading dose followed by maintenance), with therapy continued for 24 hours after delivery or the last seizure. Other anticonvulsants are reserved for refractory cases or magnesium contraindications.

• A. Levetiracetam has no established role as first-line therapy in eclampsia.
• B. Diazepam is less effective than magnesium sulfate and carries risk of neonatal respiratory depression.
• D. Phenytoin was shown to be inferior to magnesium sulfate in preventing recurrent eclamptic seizures.

Loss of deep tendon reflexes followed by respiratory depression are classic signs of magnesium sulfate toxicity, which occurs because magnesium blocks acetylcholine release at the neuromuscular junction in a dose-dependent manner. The antidote is intravenous calcium gluconate (10 mL of 10% solution given slowly), which antagonizes the neuromuscular blocking effect of magnesium. Monitoring during magnesium therapy includes hourly checks of deep tendon reflexes, respiratory rate, and urine output, since magnesium is renally excreted and toxicity risk increases with oliguria. The infusion must be stopped immediately once toxicity is suspected.

• A. Flumazenil reverses benzodiazepine toxicity and has no role here.
• B. Sodium bicarbonate is used for metabolic acidosis or certain drug overdoses, not magnesium toxicity.
• D. Naloxone is the antidote for opioid toxicity, not magnesium toxicity.

Severe hypertension in pregnancy (systolic ≥160 mmHg or diastolic ≥110 mmHg) is a hypertensive emergency requiring urgent treatment to prevent maternal stroke and other complications. Intravenous labetalol, a combined alpha- and beta-blocker, is a first-line agent along with intravenous hydralazine and oral nifedipine, acting within minutes to safely lower blood pressure without excessive placental hypoperfusion. Oral nifedipine is also acceptable but intravenous labetalol allows more rapid, titratable control in this emergency setting. ACE inhibitors are contraindicated in pregnancy due to fetotoxicity, and sodium nitroprusside is avoided due to risk of fetal cyanide toxicity.

• A. Sodium nitroprusside risks fetal cyanide toxicity and is avoided in pregnancy.
• B. ACE inhibitors such as enalapril are contraindicated in pregnancy due to teratogenicity and fetal renal damage.
• C. Oral nifedipine is an acceptable alternative but intravenous labetalol provides more rapid titratable control in this emergency.

HELLP syndrome is a severe variant of preeclampsia characterized by Hemolysis (schistocytes on smear, elevated LDH, low haptoglobin), Elevated Liver enzymes (AST/ALT), and Low Platelets (<100,000/microliter). The combination of microangiopathic hemolysis, right upper quadrant pain from hepatic capsular distension, and thrombocytopenia in a preeclamptic patient is classic for this diagnosis. Coagulation studies such as PT and fibrinogen are typically normal in HELLP, which helps distinguish it from DIC. Prompt recognition is important because definitive management is delivery, regardless of gestational age in severe cases.

• A. Acute fatty liver of pregnancy typically presents with hypoglycemia, coagulopathy, and markedly elevated bilirubin, not this pattern.
• B. DIC would show prolonged PT/aPTT and low fibrinogen, which are not mentioned here.
• D. TTP classically presents with neurological symptoms and fever, and is not linked specifically to preeclampsia.

At or beyond term (37 weeks and beyond), the definitive treatment for severe preeclampsia is delivery, since continuing the pregnancy only increases maternal and fetal risk without further fetal benefit. Mode of delivery depends on obstetric factors, with induction of labor appropriate if there is no contraindication, though cesarean section may be chosen based on cervical status and fetal condition. Magnesium sulfate should be given for seizure prophylaxis around the time of delivery. Expectant management is reserved for preterm gestations where fetal immaturity risks outweigh the benefit of prolonging pregnancy under strict surveillance.

• A. Corticosteroids for lung maturity are unnecessary at 38 weeks, and delaying delivery would increase maternal risk.
• B. Outpatient management is inappropriate given the severity of hypertension and symptoms.
• D. Expectant management is not appropriate at term since the fetus is already mature and delivery risk is lower than continued pregnancy.

Abruptio placentae classically presents with painful vaginal bleeding, a tender and tense or 'woody' hard uterus due to retroplacental hemorrhage and concealed blood, and is strongly associated with hypertensive disorders of pregnancy. Fetal distress or demise, as suggested by absent fetal heart sounds here, reflects significant placental separation compromising fetal oxygenation. In contrast, placenta previa presents with painless, bright red vaginal bleeding and a soft, non-tender uterus. The combination of pain, uterine tenderness, firmness, and hypertension strongly favors abruption over previa.

• A. Placenta previa typically causes painless bleeding with a soft, non-tender uterus, unlike the findings here.
• B. Vasa previa presents with painless bleeding at membrane rupture and fetal bradycardia without uterine tenderness or firmness.
• D. Uterine rupture typically occurs during labor with sudden severe abdominal pain and loss of uterine contour, often in a scarred uterus.

In any case of antepartum hemorrhage, a digital vaginal examination must be withheld until placenta previa has been excluded, because it can disrupt the placenta lying over or near the internal os and provoke torrential, life-threatening hemorrhage. This rule is often remembered as 'no per vaginum examination until previa is excluded.' Ultrasonography is safe and should be performed first to localize the placenta. Once previa is excluded, a sterile speculum or digital examination may be done if clinically indicated.

• A. Oxytocin is contraindicated in antepartum hemorrhage of unknown cause and does not make digital examination safe.
• C. Digital examination can dislodge the placenta from the lower segment and precipitate massive hemorrhage.
• D. Even a speculum examination carries risk and is deferred until previa is excluded by imaging.

Couvelaire uterus, also called uteroplacental apoplexy, occurs in severe abruptio placentae when blood infiltrates the myometrium and sometimes the subserosa and broad ligament, giving the uterus a mottled bluish-purple, woody appearance. It results from extensive retroplacental hemorrhage tracking through the myometrial fibers rather than from a breach in the uterine wall. Despite its dramatic appearance, it is not an indication for hysterectomy by itself; the uterus usually contracts well after delivery, though it increases the risk of postpartum atony requiring close monitoring. Management focuses on correcting coagulopathy and delivering the fetus.

• B. Uterine inversion refers to the fundus turning inside out, not myometrial blood infiltration.
• C. Uterine atony is failure of the uterus to contract after delivery, not the myometrial hemorrhagic infiltration described.
• D. Uterine rupture implies a breach in the uterine wall, which is not described here.

Vasa previa occurs when fetal vessels, unsupported by placental tissue or umbilical cord, run through the membranes over or near the internal os, often associated with velamentous cord insertion. Rupture of membranes can tear these exposed vessels, causing fetal blood loss that rapidly produces fetal bradycardia and can be fatal within minutes if delivery is delayed. The combination of membrane rupture, painless bleeding, and sudden fetal distress in a patient with known abnormal cord insertion is the classic presentation. Antenatal diagnosis by Doppler ultrasonography and planned cesarean delivery before labour prevent this catastrophic event.

• A. Placenta previa is a known risk factor for abnormal cord insertion but does not itself explain bleeding precipitated by membrane rupture with immediate fetal compromise.
• B. Uterine rupture presents with severe pain, scar tenderness, and often a history of previous cesarean section or obstructed labour.
• D. Abruption typically presents with painful bleeding and a tender, tense uterus rather than bleeding triggered by membrane rupture.

False labour, or Braxton Hicks contractions, is characterized by irregular, non-progressive contractions that do not cause cervical dilatation or effacement and are typically relieved by rest, sedation, or walking. True labour contractions are regular, increase in frequency, duration and intensity, and are associated with progressive cervical change and descent of the presenting part. The lack of cervical change despite ongoing contractions, along with relief by sedation, is the key distinguishing feature favoring false labour. Formation of the bag of forewaters and blood-stained show are features of true labour, not false labour.

• A. Descent with show indicates true labour progression.
• B. Regular, intensifying contractions are characteristic of true labour.
• D. Progressive cervical dilatation and effacement is a hallmark feature of true, not false, labour.

On the WHO partograph, the alert line marks the expected rate of cervical dilatation of 1 cm per hour from the start of the active phase, and the action line is drawn 4 hours to the right of it. A plot crossing the action line indicates poor progress in labour, and reaching or crossing the action line is an indication for reassessment, often warranting augmentation with oxytocin, exclusion of cephalopelvic disproportion, or cesarean delivery if obstruction is suspected. Adequate contractions with poor cervical progress raise concern for cephalopelvic disproportion or malposition rather than inadequate uterine activity alone. Timely action at the action line reduces the risk of obstructed labour and its complications.

• A. A plot reaching the action line in active labour is well beyond the latent phase.
• B. Crossing the action line signifies abnormal, not normal, progress and demands clinical reassessment.
• D. Crossing the action line reflects delayed progress, not successful completion of the active phase.

The described findings, failure of the shoulders to deliver with the head retracting against the perineum, known as the 'turtle sign,' indicate shoulder dystocia due to impaction of the anterior shoulder behind the symphysis pubis. The first-line maneuver is McRoberts position, hyperflexing and abducting the maternal hips onto the abdomen, combined with suprapubic pressure to dislodge the anterior shoulder, which succeeds in the majority of cases and carries minimal risk. Fundal pressure is contraindicated because it worsens impaction and increases the risk of uterine rupture and brachial plexus injury. The Zavanelli maneuver, cephalic replacement followed by cesarean, is reserved as a last resort when all other maneuvers fail.

• B. Cesarean section is not feasible once the head has already delivered; management must proceed vaginally first.
• C. Fundal pressure worsens shoulder impaction and risks uterine rupture and neonatal injury, so it is contraindicated.
• D. Zavanelli maneuver is a last-resort option reserved for failure of all standard maneuvers, not the initial step.

Active management of the third stage of labour (AMTSL) is proven to prevent postpartum haemorrhage and includes prophylactic uterotonic (oxytocin 10 IU IM/IV being first choice) given within one minute of delivery of the baby, controlled cord traction, and uterine massage after placental delivery. Oxytocin causes rhythmic uterine contractions that promote placental separation and reduce blood loss. This has been shown in multiple trials to significantly reduce the incidence of primary PPH compared to expectant management. It is recommended by WHO and FOGSI as standard practice for every delivery.

• A. Fundal massage is done after placental delivery, not before separation, and is not the primary preventive step.
• B. Manual exploration is an invasive diagnostic/therapeutic step done only if retained products are suspected, not a preventive measure.
• D. Antibiotics have no role in preventing postpartum haemorrhage.

In a patient with a favourable Bishop score (≥6-8), the cervix is already ripe and intravenous oxytocin infusion is the drug of choice for induction of labour, as it allows titratable, controlled uterine contractions with a short half-life permitting rapid cessation if hyperstimulation occurs. Prostaglandins like misoprostol or dinoprostone are preferred for cervical ripening when the Bishop score is unfavourable (<6), not for an already favourable cervix. Methylergometrine and carboprost are used for postpartum haemorrhage management, not for induction of labour.

• B. Misoprostol for induction is primarily indicated when the cervix is unfavourable; with a favourable cervix oxytocin is preferred and safer to titrate.
• C. Carboprost is a PGF2-alpha analogue used for uterine atony in PPH, not for labour induction.
• D. Methylergometrine causes sustained tonic contraction and is used for PPH management, not for induction of labour.

Uterine atony, failure of the myometrial fibers to contract and retract after delivery, is the most common cause of primary postpartum haemorrhage, accounting for nearly 70-80% of cases. Risk factors include prolonged labour, oxytocin augmentation, overdistended uterus, and grand multiparity, all present or implied here. The soft, boggy, poorly contracted uterus on palpation is the classic clinical sign distinguishing atony from other causes of PPH such as trauma or retained tissue. Prompt bimanual uterine massage and uterotonics are the mainstay of treatment.

• A. The placenta is stated to be complete, excluding retained products as the cause here.
• B. There is no clinical evidence given of coagulopathy, and it is a less common cause of primary PPH.
• D. The perineum and cervix are not described as lacerated, and a boggy uterus points to atony rather than trauma.

Methylergometrine, an ergot alkaloid, causes generalized vasoconstriction through alpha-adrenergic stimulation, which can precipitate a severe hypertensive crisis, seizures, or stroke in patients with pre-existing hypertension, pre-eclampsia, or eclampsia. It is therefore absolutely contraindicated in hypertensive patients and should be avoided in favour of safer alternatives like oxytocin or carboprost (with caution) for managing atony in such patients. This is a key prescribing safety point tested commonly in obstetric pharmacology.

• A. Oxytocin is generally safe in hypertensive patients and does not cause significant vasoconstriction at standard doses.
• C. Carboprost should be used cautiously in asthma and cardiac disease but is not primarily contraindicated due to hypertension.
• D. Misoprostol does not have hypertension as a major contraindication; it is avoided mainly in patients with significant cardiovascular disease requiring caution with prostaglandins.

When medical management of uterine atony fails and the patient remains haemodynamically stable, intrauterine balloon tamponade (such as a Bakri balloon or condom catheter tamponade) is the appropriate next step, as it is a minimally invasive, uterus-conserving technique that controls bleeding by applying pressure against the uterine walls, buying time and often avoiding surgery. If tamponade fails or the patient becomes unstable, surgical options such as uterine artery ligation, internal iliac artery ligation, or stepwise devascularization are considered before resorting to the most radical option, hysterectomy, reserved for uncontrollable haemorrhage.

• A. Hysterectomy is the last resort after conservative surgical and tamponade measures fail, not the immediate next step.
• C. Artery ligation is considered a surgical option after tamponade fails, not before it.
• D. Embolization is a radiological technique used as an alternative to surgery, not something performed after hysterectomy, which would make it redundant.

Secondary (delayed) postpartum haemorrhage occurs between 24 hours and 6 weeks after delivery, and the most common cause is retained products of conception, often associated with superimposed endometritis, presenting with foul-smelling discharge, fever, subinvolution of the uterus, and heterogeneous intrauterine contents on ultrasound, as seen here. Management typically includes antibiotics for endometritis and ultrasound-guided evacuation of retained tissue if significant retained products are confirmed. Uterine atony is a cause of primary (not secondary) PPH occurring within the first 24 hours after delivery.

• A. Cervical laceration causes immediate bright red bleeding at the time of delivery, not a delayed presentation with fever and foul discharge.
• C. There is no history or lab evidence suggesting a coagulation disorder; the clinical picture fits retained tissue with infection.
• D. Uterine atony typically causes primary PPH within the first 24 hours of delivery, not a delayed presentation like this.

Sheehan syndrome results from ischemic necrosis of the anterior pituitary following severe postpartum hemorrhage with hypovolemic shock. The pituitary enlarges during pregnancy and its blood supply becomes vulnerable to hypotension, leading to infarction. This causes panhypopituitarism, manifesting as failure of lactation (low prolactin), amenorrhea (low FSH/LH), and loss of axillary/pubic hair (low ACTH leading to adrenal androgen deficiency). It is a classic, well-described complication of massive obstetric hemorrhage.

• A. Retained products would present with fever and bleeding, not panhypopituitarism.
• B. Isolated autoimmune thyroiditis does not explain lactation failure and amenorrhea together.
• D. Adrenal infarction is not the classic mechanism in this clinical picture following PPH.

Footling presentation, a type of incomplete breech, carries a high risk of cord prolapse and head entrapment because the presenting part does not adequately dilate the cervix before the larger fetal parts descend. Current obstetric practice therefore recommends cesarean section as the preferred mode of delivery for footling breech, regardless of parity or gestational age, to reduce perinatal morbidity and mortality. Vaginal breech delivery is reserved for selected cases of complete or extended (frank) breech with favorable pelvimetry.

• A. Vaginal delivery in footling breech carries unacceptable risk of cord prolapse and entrapment of the aftercoming head.
• B. Forceps-assisted breech delivery is not appropriate when the presenting part is a foot.
• C. Internal podalic version is used for the second twin in certain situations, not as primary management of footling breech in a singleton.

The findings describe transverse lie, in which the long axis of the fetus lies perpendicular to the long axis of the uterus, with neither pole occupying the pelvic brim. Because no fetal part occupies the lower uterine segment to form a proper presenting part, there is a wide gap between the presenting part and the pelvic inlet. If the membranes rupture, the umbilical cord can easily slip down ahead of the fetal part, leading to cord prolapse, an obstetric emergency requiring immediate cesarean section.

• B. Shoulder dystocia occurs during vaginal delivery of a cephalic presentation with impaction of the shoulders, not applicable in transverse lie.
• C. Placenta accreta is an abnormality of placental attachment, not a direct consequence of transverse lie.
• D. Vasa previa refers to fetal vessels crossing the membranes over the cervix, unrelated to lie of the fetus.

In face presentation, the denominator is the mentum (chin). When the mentum is posterior, meaning it points toward the maternal sacrum, the fetal neck would have to hyperextend further for the head to pass under the symphysis pubis, which is mechanically impossible once the head is deep in the pelvis. Persistent mentoposterior position therefore results in obstructed labor, and cesarean section is required. Mentoanterior positions, in contrast, can often deliver vaginally after the chin rotates anteriorly.

• A. Cord prolapse is not a direct feature of mentoposterior position.
• B. Face presentation is a longitudinal lie with extension of the head, not a transverse lie.
• D. Face presentation actually presents a larger, not smaller, presenting diameter (mentovertical) and does not ease delivery.

The findings of short maternal stature, arrest of cervical dilatation and descent despite adequate contractions, and a positive Munro Kerr sign (overriding of the fetal head on the symphysis pubis) indicate cephalopelvic disproportion. When CPD is confirmed in active labor with good contractions, further trial of labor is unsafe because it risks obstructed labor, uterine rupture, and fetal compromise. Cesarean section is the definitive and safest management.

• B. Rupturing membranes does not resolve disproportion and may worsen cord compression or precipitate cord prolapse.
• C. Oxytocin augmentation is contraindicated once CPD is diagnosed, as it increases the risk of uterine rupture without aiding delivery.
• D. Forceps delivery requires an engaged head and adequate pelvis, both absent in confirmed CPD.

Twin-to-twin transfusion syndrome occurs in monochorionic diamniotic twin pregnancies due to unbalanced blood flow through placental vascular anastomoses. It is diagnosed sonographically by the finding of oligohydramnios (maximum vertical pocket less than 2 cm) in the donor twin, who may appear "stuck" against the uterine wall, together with polyhydramnios (maximum vertical pocket more than 8 cm) in the recipient twin, who also typically has a distended bladder from increased urine output. This discordance in amniotic fluid volume, rather than discordance in estimated fetal weight alone, is the defining criterion.

• A. Vanishing twin syndrome refers to early loss and resorption of one twin, not a finding at 22 weeks with both twins present.
• B. TRAP sequence involves an acardiac twin perfused by the co-twin through retrograde arterial flow, not fluid discordance alone.
• D. Selective IUGR is defined by significant weight discordance between twins, which is absent here since weights are similar.

The triangular projection of placental tissue into the base of the intertwin membrane is the lambda or twin peak sign, seen in dichorionic placentation because two separate chorionic plates fuse and interdigitate at the junction. Monochorionic placentas show a thin membrane meeting the placenta at a right angle, producing the T sign instead. Correct chorionicity assignment by 14 weeks is essential because monochorionic twins carry higher risk of twin-to-twin transfusion syndrome and need closer surveillance. The lambda sign is most reliable when assessed in the first trimester as it can become less distinct later in pregnancy.

• A. This pregnancy shows the lambda sign, not the T sign seen with a thin monochorionic membrane.
• B. Monoamniotic twins have no intertwin membrane at all, which is not the case here.
• D. Conjoined twins are diagnosed by failure to demonstrate separate fetal bodies, not by membrane morphology.

Asymmetric IUGR, with relative sparing of the head compared to the abdomen, results from uteroplacental insufficiency occurring later in pregnancy, after organogenesis is complete. The fetus adapts by redistributing cardiac output preferentially to the brain, heart and adrenal glands at the expense of the liver, gut and subcutaneous tissue, reducing abdominal circumference and liver glycogen stores. Symmetric IUGR, in contrast, reflects an insult acting early in pregnancy, such as chromosomal abnormality or congenital infection, causing proportionate reduction in both head and body size. Recognizing the pattern helps identify the likely timing and cause of growth restriction.

• A. Aneuploidy causes a symmetric pattern of growth restriction from early gestation onward.
• B. An early, global insult such as infection typically produces symmetric growth restriction affecting the head and body equally.
• D. Early teratogenic exposure causing structural or cellular insult usually produces symmetric growth restriction.

Rh-negative, non-sensitized women with no history of antibody formation should receive a prophylactic dose of anti-D immunoglobulin at around 28 weeks of gestation to neutralize fetal red cells that may have crossed into the maternal circulation during the third trimester. A second dose is given within 72 hours of delivery if the newborn is confirmed Rh positive, since this is the time of greatest fetomaternal hemorrhage. Anti-D works by binding fetal Rh-positive cells before the maternal immune system can mount a primary antibody response, preventing future hemolytic disease of the newborn in subsequent pregnancies. Anti-D is not given once the mother is already sensitized, since it cannot reverse established antibody formation.

• A. Giving anti-D only after delivery misses third-trimester sensitization risk, which the 28-week dose is designed to prevent.
• B. A single dose at 12 weeks does not cover the ongoing risk of sensitization through the remainder of pregnancy and delivery.
• C. Once the indirect Coombs test is positive, the woman is already sensitized and anti-D immunoglobulin is no longer of benefit.

The Diabetes in Pregnancy Study Group India (DIPSI) criteria recommend a single-step 75 g oral glucose tolerance test performed irrespective of fasting status, with a 2-hour venous plasma glucose value of 140 mg/dL or more confirming gestational diabetes mellitus. This approach was adopted for universal screening under India's National Health Mission because it avoids the need for fasting and simplifies testing in a high-volume antenatal population. A single abnormal value is sufficient for diagnosis, unlike the two-step approach used in some Western guidelines. Early detection allows timely dietary and pharmacological management to reduce macrosomia and perinatal complications.

• A. A 2-hour value of 100 mg/dL is within the normal range and does not meet the diagnostic threshold.
• B. 126 mg/dL is the fasting plasma glucose cutoff for diabetes diagnosis, not the 2-hour post-load value used in the DIPSI test.
• D. 200 mg/dL would suggest overt diabetes rather than being the standard screening cutoff for gestational diabetes.

Insulin is the preferred agent for glycemic control in pregnant women with pregestational diabetes because it does not cross the placenta in significant amounts and allows precise, flexible dose titration to meet the changing insulin requirements of pregnancy. Sulfonylureas such as glimepiride cross the placenta and can cause fetal hyperinsulinemia and neonatal hypoglycemia, so they are discontinued. Although metformin has some accepted use in gestational diabetes, in a woman with pregestational type 2 diabetes with suboptimal control, insulin is preferred for tighter and more predictable glycemic targets throughout pregnancy. Good glycemic control from early pregnancy reduces the risk of congenital malformations, macrosomia, and birth trauma.

• B. Although metformin has some role in gestational diabetes, insulin is preferred for a pregestational diabetic with an HbA1c this elevated.
• C. Continuing sulfonylureas in pregnancy risks placental transfer and neonatal hypoglycemia, and her current control is inadequate.
• D. Sodium-glucose cotransporter-2 inhibitors are not recommended in pregnancy due to insufficient safety data and are not used in pregestational diabetes management.

Sodium valproate taken during the first trimester, particularly during the period of neural tube closure between 3 and 4 weeks post-conception, is strongly associated with neural tube defects such as spina bifida, through mechanisms including folate antagonism and histone deacetylase inhibition. The risk is dose-dependent and substantially higher than with other commonly used antiepileptics. Because of this and its association with lower IQ and other congenital anomalies, valproate is avoided in women of reproductive age wherever possible, and alternative antiepileptics with better safety profiles are preferred during pregnancy. Periconceptional high-dose folic acid supplementation is advised for women who must continue valproate.

• A. Phenytoin is associated with fetal hydantoin syndrome and craniofacial anomalies rather than neural tube defects.
• B. Levetiracetam has a comparatively favorable safety profile in pregnancy and is not strongly linked to neural tube defects.
• D. Lamotrigine is among the preferred antiepileptics in pregnancy and carries a much lower risk of major malformations than valproate.

The ampulla is the longest and widest segment of the fallopian tube and is the most common site for fertilization, making it the most frequent location for tubal ectopic implantation, accounting for over half of all cases. The isthmus and interstitial regions are narrower and less commonly involved, while ovarian and abdominal ectopics are rare. Awareness of site frequency helps anticipate presentation and surgical approach. Rupture risk and timing vary with site, with isthmic ectopics rupturing earlier due to the narrow lumen.

• A. The isthmus is a less common site and ruptures earlier due to its narrow lumen, but is not the most frequent location.
• C. Ovarian ectopic pregnancy is uncommon and accounts for a small fraction of cases.
• D. The interstitial part is a rare but dangerous site due to proximity to uterine vessels, not the commonest location.

In a stable patient, a beta-hCG level below the discriminatory zone (usually 1500-2000 mIU/mL) with an empty uterus on TVS is inconclusive for intrauterine versus ectopic pregnancy, so serial beta-hCG at 48-hour intervals is required. A normally doubling value (rise of at least 53-66%) suggests a viable intrauterine pregnancy that may simply be too early to visualize, whereas a plateauing or slowly rising value raises suspicion of ectopic pregnancy. Laparotomy and methotrexate are premature without confirming diagnosis or location. This correlation of trend with ultrasound findings is the standard diagnostic algorithm.

• A. An empty uterus at this beta-hCG level cannot be assumed normal; ectopic pregnancy must be excluded first.
• B. Emergency surgery is unwarranted in a hemodynamically stable patient without a confirmed diagnosis.
• C. Methotrexate should not be given before the diagnosis and location of pregnancy are confirmed.

Methotrexate is suitable for hemodynamically stable patients with an unruptured ectopic mass generally smaller than 3.5-4 cm, no visible fetal cardiac activity, and beta-hCG levels ideally below 5000 mIU/mL, since higher levels and larger masses are associated with higher failure rates. The absence of cardiac activity reduces the risk associated with ongoing trophoblastic growth, improving success with medical therapy. High beta-hCG and large mass size predict medical treatment failure and favor surgery. Presence of hemoperitoneum signals possible rupture, which is an absolute contraindication to methotrexate.

• A. A large mass with cardiac activity present favors surgical rather than medical management.
• B. Hemoperitoneum suggests rupture or ongoing bleeding, an absolute contraindication to medical management.
• C. Beta-hCG above 5000 mIU/mL substantially reduces the success rate of methotrexate therapy.

A complete mole arises from fertilization of an empty ovum by a single sperm that duplicates, or by two sperm, producing a diploid karyotype that is entirely paternal in origin with no fetal parts. Ultrasound characteristically shows a diffuse vesicular pattern described as a snowstorm appearance without a coexisting fetus. Partial moles, in contrast, have triploid karyotype with both maternal and paternal contribution and often a coexisting abnormal fetus. The absence of fetal tissue and purely paternal diploid karyotype confirm complete mole in this scenario.

• A. A partial mole is triploid with maternal and paternal chromosomal contribution and usually has an associated fetus or fetal parts.
• B. Hydropic degeneration of a missed abortion does not show a purely paternal diploid karyotype or markedly elevated beta-hCG.
• C. Invasive mole is a complication defined by myometrial invasion, not the initial diagnosis based on these findings.

After molar evacuation, weekly serum beta-hCG is monitored until three consecutive weekly values are normal, followed by monthly monitoring for six months to detect persistent or malignant trophoblastic disease early. Reliable contraception is advised during this follow-up period to avoid confusion between a new pregnancy and recurrence. A single measurement or symptom-triggered testing would miss asymptomatic gestational trophoblastic neoplasia, which can develop without bleeding. Ultrasound alone is not sensitive enough to replace quantitative beta-hCG trends in this setting.

• A. A single measurement is inadequate since persistent trophoblastic disease can develop over weeks to months.
• B. Ultrasound without beta-hCG monitoring is not sensitive enough to detect biochemical persistence.
• D. Relying only on symptoms would miss asymptomatic cases of persistent or malignant trophoblastic disease.

The Rotterdam criteria diagnose polycystic ovarian syndrome when at least two of three features are present: oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound, after exclusion of other causes such as thyroid dysfunction and hyperprolactinemia. This patient has oligomenorrhea, clinical hyperandrogenism with hirsutism supported by raised testosterone, and polycystic ovarian morphology, satisfying all three criteria. An elevated LH:FSH ratio is a supportive but not diagnostic feature, and ultrasound findings or testosterone elevation alone are insufficient without correlating clinical features. Excluding other endocrine disorders is an essential part of the Rotterdam approach.

• A. A raised LH:FSH ratio is a supportive finding in PCOS but is not part of the formal diagnostic criteria.
• C. Testosterone elevation alone, without oligo-ovulation or ultrasound findings, does not fulfill the diagnostic criteria.
• D. Ovarian enlargement alone on ultrasound, without other clinical or biochemical criteria, is insufficient for diagnosis.

Combined oral contraceptive pills act mainly by suppressing the hypothalamic-pituitary-ovarian axis: the estrogen and progestin components inhibit GnRH pulsatility, which blunts the mid-cycle LH surge and prevents ovulation. Progestin also thickens cervical mucus and causes endometrial changes unfavorable to implantation, but these are secondary mechanisms. Ovulation inhibition is the most consistent and primary contraceptive mechanism of combined pills. This distinguishes them from progestin-only minipills, which rely more on cervical mucus thickening since ovulation is not always suppressed.

• A. Cervical mucus thickening is a secondary, not the primary, mechanism of combined pills.
• C. This describes the mechanism of copper IUCDs, not hormonal contraceptives.
• D. Combined pills slow, not accelerate, tubal motility; this is not their main mechanism.

The combination of smoking, age over 35 years, and obesity significantly raises the risk of venous thromboembolism and arterial events with combined oral contraceptives because estrogen increases hepatic synthesis of clotting factors and reduces fibrinolysis. WHO medical eligibility criteria classify heavy smoking in women over 35 as a strong contraindication to combined pills. Such women should be offered progestin-only or non-hormonal methods instead. This adverse effect is the leading cause of serious morbidity attributed to combined pill use.

• A. Combined pills actually decrease the incidence of functional ovarian cysts.
• C. Combined pills reduce, not increase, the risk of endometrial hyperplasia and cancer.
• D. Combined pills reduce menstrual blood loss and are protective against iron deficiency anemia.

The copper-bearing intrauterine device acts mainly by inducing a sterile, copper ion-mediated inflammatory reaction within the endometrial cavity, which is toxic to sperm and ova and impairs fertilization; it does not suppress ovulation. Postpartum insertion can be done within 48 hours of delivery or, if missed, is deferred until after 4 to 6 weeks (postpartum/interval insertion) to reduce the risk of expulsion and perforation, which is why 6 weeks postpartum is an appropriate timing. Copper IUCDs are a non-hormonal, long-acting reversible method of contraception.

• A. The device sits within the uterine cavity and acts on the endometrium, not by blocking the cervical canal.
• B. Copper IUCDs do not suppress ovulation; women continue to ovulate normally.
• D. This describes the mechanism of the levonorgestrel-releasing intrauterine system, not the copper-T.

The quadrivalent HPV vaccine protects against serotypes 6 and 11, which cause genital warts, and 16 and 18, which are responsible for about 70 percent of cervical cancers. It is most immunogenic and effective when given to girls aged 9 to 14 years, ideally before the onset of sexual activity and before exposure to HPV. The vaccine does not treat existing infection, so early administration before coitarche maximizes protective benefit. The World Health Organization recommends this age group as the primary target for national HPV vaccination programs.

• A. This bivalent description is incomplete, and the target population for maximum benefit is pre-adolescent girls, not adult men.
• B. There is no HPV serotype numbered 1 to 4 relevant to cervical cancer; this option is fabricated.
• C. Serotypes 31 and 33 are not the main vaccine targets, and vaccination has no benefit after lesions are already established in older women.

Alpha-fetoprotein is the characteristic tumor marker for yolk sac (endodermal sinus) tumors of the ovary, a germ cell tumor that typically occurs in young women and adolescents and grows rapidly. CA-125 is more useful for epithelial ovarian tumors, particularly serous cystadenocarcinoma, in postmenopausal women. Beta hCG is elevated in choriocarcinoma and some mixed germ cell tumors, while lactate dehydrogenase is the classic marker for dysgerminoma. Recognizing marker-tumor correlation helps guide diagnosis and post-treatment surveillance in ovarian germ cell tumors.

• A. Lactate dehydrogenase is the classic marker for dysgerminoma, not yolk sac tumor.
• B. CA-125 is associated with epithelial ovarian tumors such as serous cystadenocarcinoma, not yolk sac tumors.
• C. Beta hCG is characteristically elevated in choriocarcinoma, not yolk sac tumors.

Any postmenopausal bleeding associated with an endometrial thickness greater than 4 to 5 mm on transvaginal ultrasound warrants histological evaluation to rule out endometrial carcinoma, as this is the most common gynecological malignancy presenting with postmenopausal bleeding in this age group. Endometrial biopsy, obtained by dilatation and curettage or hysteroscopy-guided sampling, provides a definitive tissue diagnosis and is the standard next step. Delaying diagnosis with repeat imaging or reassurance risks missing a treatable early-stage cancer. CA-125 is not a diagnostic test for endometrial cancer and does not substitute for histopathology.

• A. Delaying evaluation risks missing an early endometrial malignancy; biopsy should not be postponed in this high-risk finding.
• C. CA-125 is not used to diagnose endometrial carcinoma and cannot replace tissue sampling.
• D. Atrophic endometrium does not cause a thickened, heterogeneous endometrium of 14 mm; this thickness mandates biopsy to exclude malignancy.

Leiomyoma (fibroid) is a uterine mass, so it moves with cervical traction on bimanual examination, a key clinical sign distinguishing it from an ovarian or adnexal mass. The whorled, hypoechoic appearance on ultrasound arising from the myometrium is classic for fibroids. Ascites, raised CA-125, and bilateral complex adnexal masses point toward ovarian malignancy rather than a benign uterine fibroid. Fibroids are diagnosed primarily by clinical examination and confirmed with ultrasound showing a well-defined myometrial mass.

• A. CA-125 elevation is associated with ovarian malignancy and endometriosis, not typically with uterine fibroids.
• B. Ascites suggests ovarian malignancy or Meigs syndrome, not a simple fibroid.
• D. Bilateral complex adnexal masses suggest ovarian pathology, not a uterine fibroid.

In the POP-Q staging system, Stage III is defined as the leading edge of the prolapse descending more than 1 cm beyond the hymenal plane but not to within 2 cm of the total vaginal length (not complete eversion). A descent of 2 cm beyond the hymen fits this criterion. Stage II is when the leading edge is within 1 cm proximal or distal to the hymen. Stage IV represents complete eversion of the vaginal canal. POP-Q is the objective, reproducible method recommended for staging prolapse, replacing older descriptive classifications.

• A. Stage II means the leading edge is within 1 cm proximal or distal to the hymen, not 2 cm beyond it.
• C. Stage IV indicates complete vaginal eversion, with the leading edge at or beyond (total vaginal length minus 2 cm), not just 2 cm past the hymen.
• D. Stage I means the leading edge is more than 1 cm above the hymenal plane, not applicable here.